RBT will focus on vaccine development projects, where it will control the full cycle — from the development of its own antigen to the finished product. One of these areas is a range of high—margin vaccines for animals. Company also plans to switch to a licensed business model with the transfer of rights to drugs before obtaining a registration certificate.

RBT and the Almazov Center have signed an agreement on cooperation in research and development activities in order to develop and implement innovative medical technologies and products in practical healthcare. As part of the agreement, the parties planned to develop and market solutions for organ preservation, targeted drug delivery systems, drugs for the tr...

Board of Directors of Artgen Biotech terminated the agreement with Natsimbio on joint development of RBT vaccine for influenza and covid prophylaxis due to the delay in terms of organizing and conducting clinical trials. Ministry of Health allowed to conduct studies until December 31, 2024, but they never took place. Now RBT will independently prepare a doss...

Artgen Biotech Group is investing in the development of a platform for creating new subunit vaccines based on surface recombinant proteins and spherical adjuvant particles. Developer of the technology platform is RBT, a company within the Artgen Biotech group. Total investment in the development of the production component of the platform by RBT, including f...